<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>allergy and immunology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>allergy and immunology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses
Authors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/allergy-and-immunology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="allergy and immunology" />
<meta property="og:description" content="Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses
Authors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/allergy-and-immunology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-10-01T10:37:47+00:00" />
<meta property="article:modified_time" content="2023-10-01T10:37:47+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="allergy and immunology"/>
<meta name="twitter:description" content="Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses
Authors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "allergy and immunology",
      "item": "https://trxiv.yorks0n.com/posts/allergy-and-immunology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "allergy and immunology",
  "name": "allergy and immunology",
  "description": "Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses\nAuthors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A.",
  "keywords": [
    
  ],
  "articleBody": " Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses\nAuthors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A.-C.; Decaluwe, H.; Gommerman, J. L.\nScore: 24.3, Published: 2023-09-29 DOI: 10.1101/2023.09.22.23295541\nOur understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show that mild BT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary IgG and IgA levels against the Omicron Spike and enhanced reactivity to the ancestral Spike for the IgA isotype, which also reacted with SARS-CoV-1. Serum neutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for mucosal vaccines to emulate the enhanced mucosal and humoral immunity induced by Omicron without exposing individuals to the risks associated with SARS-CoV-2 infection. ONE SENTENCE SUMMARYOmicron breakthrough elicits cross-reactive systemic and mucosal immune responses in fully vaccinated adults. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=119 SRC=\"FIGDIR/small/23295541v1_ufig1.gif\" ALT=\"Figure 1\"\u003e View larger version (27K): org.highwire.dtl.DTLVardef@427c62org.highwire.dtl.DTLVardef@f43853org.highwire.dtl.DTLVardef@19e1035org.highwire.dtl.DTLVardef@3a2419_HPS_FORMAT_FIGEXP M_FIG C_FIG\nThe assembly of neutrophil inflammasomes during COVID-19 is mediated by type I interferons\nAuthors: Cabrera, L. E.; Jokiranta, S. T.; Mäki, S.; Miettinen, S.; Kant, R.; Kareinen, L.; Sironen, T.; Pietilä, J.-P.; Kantele, A.; Kekäläinen, E.; Lindgren, H.; Mattila, P.; Kipar, A.; Vapalahti, O.; Strandin, T.\nScore: 4.8, Published: 2023-09-14 DOI: 10.1101/2023.09.07.23295190\nThe severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a critical arm of the innate immune response and are major mediators of inflammation, but their role in COVID-19 pathophysiology remains poorly understood. We conducted transcriptomic profiling of neutrophils obtained from patients with mild and severe COVID-19, as well as from SARS-CoV-2 infected mice, in comparison to non-infected healthy controls. In addition, we investigated the inflammasome formation potential in neutrophils from patients and mice upon SARS-CoV-2 infection. Transcriptomic analysis of polymorphonuclear cells (PMNs), consisting mainly of mature neutrophils, revealed a striking type I interferon (IFN-I) gene signature in severe COVID-19 patients, contrasting with mild COVID-19 and healthy controls. Notably, low-density granulocytes (LDGs) from severe COVID-19 patients exhibited an immature neutrophil phenotype and lacked this IFN-I signature. Moreover, PMNs from severe COVID-19 patients showed heightened nigericin-induced caspase1 activation, but reduced responsiveness to exogenous inflammasome priming. Furthermore, IFN-I emerged as a priming stimulus for neutrophil inflammasomes, which was confirmed in a COVID-19 mouse model. These findings underscore the crucial role of neutrophil inflammasomes in driving inflammation during severe COVID-19, with mature neutrophils displaying heightened inflammasome activity and exhibiting a distinctive IFN-I gene signature. Altogether, these findings open promising avenues for targeted therapeutic interventions to mitigate the pathological processes associated with the disease.\nInfluence of age, sex, body habitus, vaccine type and anti-S serostatus on cellular and humoral responses to SARS-CoV-2 vaccination\nAuthors: Chambers, E. S.; Cai, W.; Cousens, A. K.; Vivaldi, G.; Jolliffe, D. A.; Perdek, N.; Li, W.; Faustini, S. E.; Gibbons, J. M.; Pade, C.; Richter, A. G.; Martineau, A. R.\nScore: 1.1, Published: 2023-09-29 DOI: 10.1101/2023.09.29.23296222\nVaccine development targeting SARS-CoV-2 in 2020 was of critical importance in reducing COVID-19 severity and mortality. In the U.K. during the initial roll-out most individuals either received two doses of Pfizer COVID-19 vaccine (BNT162b2) or the adenovirus-based vaccine from Oxford/AstraZeneca (ChAdOx1-nCoV-19). There are conflicting data as to the impact of age, sex and body habitus on cellular and humoral responses to vaccination, and most studies in this area have focused on determinants of mRNA vaccine immunogenicity. Here we studied a cohort of participants in a population-based longitudinal study (COVIDENCE UK) to determine the influence of age, sex, body mass index (BMI) and pre-vaccination anti-Spike (anti-S) antibody status on vaccine-induced humoral and cellular immune responses to two doses of BNT162b2 or ChAdOx-n-CoV-19 vaccination. Younger age and pre-vaccination anti-S seropositivity were both associated with stronger antibody responses to vaccination. BNT162b2 generated higher neutralising and anti-S antibody titres to vaccination than ChAdOx1-nCoV-19, but cellular responses to the two vaccines were no different. Irrespective of vaccine type, increasing age was also associated with decreased frequency of cytokine double-positive CD4+ T cells. Increasing BMI was associated with reduced frequency of SARS-CoV-2-specific TNF+ CD8% T cells for both vaccines. Together, our findings demonstrate that increasing age and BMI associate with attenuated cellular and humoral responses to SARS-CoV-2 vaccination. Whilst both vaccines induced T cell responses, BNT162b2 induced significantly elevated humoral immune response as compared to ChAdOx-n-CoV-19.\n",
  "wordCount" : "848",
  "inLanguage": "en",
  "datePublished": "2023-10-01T10:37:47Z",
  "dateModified": "2023-10-01T10:37:47Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/allergy-and-immunology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      allergy and immunology
    </h1>
    <div class="post-meta"><span>updated on October 1, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.22.23295541">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.22.23295541" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.22.23295541">
        <p class="paperTitle">Comparison of immunity induced by Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic antibody responses</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.22.23295541" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.22.23295541" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Nantel, S.; Sheikh-Mohamed, S.; Chao, G. Y. C.; Kurtesi, A.; Hu, Q.; Wood, H.; Colwill, K.; Li, Z.; Liu, Y.; Seifried, L.; Bourdin, B.; McGeer, A.; Hardy, W. R.; Rojas, O. L.; Ostrowski, M. A.; Brockman, M. A.; Piccirillo, C. A.; Quach, C.; Rini, J. M.; Gingras, A.-C.; Decaluwe, H.; Gommerman, J. L.</p>
        <p class="info">Score: 24.3, Published: 2023-09-29 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.22.23295541' target='https://doi.org/10.1101/2023.09.22.23295541'> 10.1101/2023.09.22.23295541</a></p>
        <p class="abstract">Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show that mild BT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary IgG and IgA levels against the Omicron Spike and enhanced reactivity to the ancestral Spike for the IgA isotype, which also reacted with SARS-CoV-1. Serum neutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for mucosal vaccines to emulate the enhanced mucosal and humoral immunity induced by Omicron without exposing individuals to the risks associated with SARS-CoV-2 infection.

ONE SENTENCE SUMMARYOmicron breakthrough elicits cross-reactive systemic and mucosal immune responses in fully vaccinated adults.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=119 SRC=&#34;FIGDIR/small/23295541v1_ufig1.gif&#34; ALT=&#34;Figure 1&#34;&gt;
View larger version (27K):
org.highwire.dtl.DTLVardef@427c62org.highwire.dtl.DTLVardef@f43853org.highwire.dtl.DTLVardef@19e1035org.highwire.dtl.DTLVardef@3a2419_HPS_FORMAT_FIGEXP  M_FIG C_FIG</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.07.23295190">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.07.23295190" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.07.23295190">
        <p class="paperTitle">The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I interferons</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.07.23295190" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.07.23295190" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Cabrera, L. E.; Jokiranta, S. T.; Mäki, S.; Miettinen, S.; Kant, R.; Kareinen, L.; Sironen, T.; Pietilä, J.-P.; Kantele, A.; Kekäläinen, E.; Lindgren, H.; Mattila, P.; Kipar, A.; Vapalahti, O.; Strandin, T.</p>
        <p class="info">Score: 4.8, Published: 2023-09-14 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.07.23295190' target='https://doi.org/10.1101/2023.09.07.23295190'> 10.1101/2023.09.07.23295190</a></p>
        <p class="abstract">The severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a critical arm of the innate immune response and are major mediators of inflammation, but their role in COVID-19 pathophysiology remains poorly understood. We conducted transcriptomic profiling of neutrophils obtained from patients with mild and severe COVID-19, as well as from SARS-CoV-2 infected mice, in comparison to non-infected healthy controls. In addition, we investigated the inflammasome formation potential in neutrophils from patients and mice upon SARS-CoV-2 infection. Transcriptomic analysis of polymorphonuclear cells (PMNs), consisting mainly of mature neutrophils, revealed a striking type I interferon (IFN-I) gene signature in severe COVID-19 patients, contrasting with mild COVID-19 and healthy controls. Notably, low-density granulocytes (LDGs) from severe COVID-19 patients exhibited an immature neutrophil phenotype and lacked this IFN-I signature. Moreover, PMNs from severe COVID-19 patients showed heightened nigericin-induced caspase1 activation, but reduced responsiveness to exogenous inflammasome priming. Furthermore, IFN-I emerged as a priming stimulus for neutrophil inflammasomes, which was confirmed in a COVID-19 mouse model. These findings underscore the crucial role of neutrophil inflammasomes in driving inflammation during severe COVID-19, with mature neutrophils displaying heightened inflammasome activity and exhibiting a distinctive IFN-I gene signature. Altogether, these findings open promising avenues for targeted therapeutic interventions to mitigate the pathological processes associated with the disease.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.29.23296222">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.29.23296222" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.29.23296222">
        <p class="paperTitle">Influence of age, sex, body habitus, vaccine type and anti-S serostatus on cellular and humoral responses to SARS-CoV-2 vaccination</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.29.23296222" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.29.23296222" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Chambers, E. S.; Cai, W.; Cousens, A. K.; Vivaldi, G.; Jolliffe, D. A.; Perdek, N.; Li, W.; Faustini, S. E.; Gibbons, J. M.; Pade, C.; Richter, A. G.; Martineau, A. R.</p>
        <p class="info">Score: 1.1, Published: 2023-09-29 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.29.23296222' target='https://doi.org/10.1101/2023.09.29.23296222'> 10.1101/2023.09.29.23296222</a></p>
        <p class="abstract">Vaccine development targeting SARS-CoV-2 in 2020 was of critical importance in reducing COVID-19 severity and mortality. In the U.K. during the initial roll-out most individuals either received two doses of Pfizer COVID-19 vaccine (BNT162b2) or the adenovirus-based vaccine from Oxford/AstraZeneca (ChAdOx1-nCoV-19). There are conflicting data as to the impact of age, sex and body habitus on cellular and humoral responses to vaccination, and most studies in this area have focused on determinants of mRNA vaccine immunogenicity. Here we studied a cohort of participants in a population-based longitudinal study (COVIDENCE UK) to determine the influence of age, sex, body mass index (BMI) and pre-vaccination anti-Spike (anti-S) antibody status on vaccine-induced humoral and cellular immune responses to two doses of BNT162b2 or ChAdOx-n-CoV-19 vaccination. Younger age and pre-vaccination anti-S seropositivity were both associated with stronger antibody responses to vaccination. BNT162b2 generated higher neutralising and anti-S antibody titres to vaccination than ChAdOx1-nCoV-19, but cellular responses to the two vaccines were no different. Irrespective of vaccine type, increasing age was also associated with decreased frequency of cytokine double-positive CD4&#43; T cells. Increasing BMI was associated with reduced frequency of SARS-CoV-2-specific TNF&#43; CD8% T cells for both vaccines. Together, our findings demonstrate that increasing age and BMI associate with attenuated cellular and humoral responses to SARS-CoV-2 vaccination. Whilst both vaccines induced T cell responses, BNT162b2 induced significantly elevated humoral immune response as compared to ChAdOx-n-CoV-19.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
